-+ 0.00%
-+ 0.00%
-+ 0.00%

Poolbeg Pharma's Cytokine Release Syndrome Preventative Therapy Trial Bags Positive Interim Safety Review

MT Newswires·09/24/2026 03:24:52
Listen to the news
03:24 AM EDT, 09/24/2026 (MT Newswires) -- Poolbeg Pharma (POLB.L) said Thursday that its Topical clinical trial of Polb 001 will continue as planned following a positive review of data from the interim safety cohort. The review recommended that the trial continue without any changes to the study protocol. The drug candidate is being developed to prevent Cytokine Release Syndrome, a life-threatening side effect in cancer immunotherapies. The clinical-stage biopharmaceutical company expects to generate further data and share it with prospective partners.